secwatch.observer — SEC 8-K summary
======================================

Issuer:     Merck & Co., Inc. (MRK)
CIK:        0000310158
Form:       8-K
Filed at:   2022-04-28T23:59:59+00:00
Accession:  0001104659-22-051588
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck Q1 sales $15.9B (+50% YoY); Non-GAAP EPS $2.14; raises full-year guidance
-------------------------------------------------------------------------------

- Sales $15.9B, +50% YoY (52% ex-FX); KEYTRUDA $4.8B (+23%), LAGEVRIO contributed $3.2B.
- GAAP EPS $1.70 vs $1.08; Non-GAAP EPS $2.14 vs $1.16, both well above prior year.
- Raises 2022 sales guidance to $56.9-$58.1B (17-19% growth); Non-GAAP EPS guidance $7.24-$7.36.
- JANUVIA/JANUMET sales fell 5% to $1.2B; expect loss of EU/China exclusivity in Q3 2022.
- Pipeline progress: FDA approvals for KEYTRUDA in MSI-H endometrial cancer and Lynparza in adjuvant breast cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/0001104659-22-051588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/310158/000110465922051588/tm2213615d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-051588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer